Lepu Medical
Lepu Medical
Engaged in the R&D, production and sales of cardiovascular disease plant intervention diagnosis and treatment equipment and cardiovascular drugs.
Lepu Medical, founded in June, 1999 and headquartered in Beijing, is an enterprise engaged in the R&D, production and sales of cardiovascular drugs and cardiovascular disease plant interventional diagnosis and treatment equipment . The founder is Pu Zhongjie. Listed on the SZSE on October 30, 2009, the company's major shareholders are Luoyang Ship Material Research Institute, Pu Zhongjie and WP Medical Technologies, INC. Rivals that have direct and indirect competition with Lepu Medical include Peijia, Kintor, Aprea Therapeutics, Viela, etc.
- All
- News
- Analysis
- Research
Briefing Jun 24, 2022 11:15 AM
· Healthcare
F-star to be acquired by China biopharmaceutical with USD 161million
Briefing Jun 24, 2022 11:07 AM
· Healthcare
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
In-depth
Healthcare
Artificial Intelligence and Interventional Surgical Robots
The evolvement and implementation of artificial intelligence (AI) are dramatically changing the medical landscape, and the potential benefits of using AI in interventional medicine are now also being extensively pursued. The article focuses primarily on advances and challenges in AI applied to interventional surgical robots.
Nov 03, 2022 06:11 PM
Briefing Jun 24, 2022 10:46 AM
· Healthcare
East China medicine "liraglutide" goes to sea
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Apr 22, 2021 03:11 PM
Briefing Jun 23, 2022 06:25 PM
· Healthcare
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Briefing Jun 23, 2022 06:24 PM
· Healthcare
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Briefing Jun 23, 2022 10:36 AM
· Healthcare
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
Briefing Jun 23, 2022 10:27 AM
· Healthcare
Yanye new crown drug 3CL protein inhibitor has been suspended approval
Insight
Healthcare
Challenges and Opportunities Possessed by Digital Therapeutics Industry
Following the digital therapeutics series report, this article is centered on the challenges and opportunities faced by the digital therapeutics industry and aims to provide insights on the two above aspects.
Nov 23, 2022 03:23 PM
Healthcare
Daxiang Biotech Bags Nearly CNY 100 Mn in Series Pre-B Financing Round
Daxiang Biotech, China's leading company in organoids-on-chips, will accelerate drug development and clinical precision therapy and promote the Organoid-on-Chips technology with the fresh proceeds.
Nov 15, 2022 12:56 PM
Briefing Jun 23, 2022 10:24 AM
· Healthcare
Sanofi Greater China will be headed by Shi Wang, and Henting he will become the global head of the digital business unit
Briefing Jul 20, 2021 07:03 PM
· Healthcare
State Affairs Office: revise and issue the negative list of market access (2021 version) before the end of the year to carry out the pilot of relaxing market access
See more
Related Companies
EqualOcean Analysis